Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multimodal EEG-fNIRS classification as a clinical tool for bipolar disorder diagnosis.

Translational psychiatry·2026

Same author

Anomalous Pressure Dependence of the Charge Density Wave and Fermi Surface Reconstruction in BaFe_{2}Al_{9}.

Physical review letters·2025

Same author

Rapid synthesis process and characterization for high purity sodium thioantimoniate nonahydrate.

Dalton transactions (Cambridge, England : 2003)·2022

Same author

Monthly anomaly database of atmospheric and oceanic parameters in the tropical Atlantic ocean.

Data in brief·2022

Same author

Omasal flow of nonstructural carbohydrates and nitrogenous compounds in lactating dairy cows fed diets containing timothy cut in the afternoon or morning.

Journal of dairy science·2021

Same author

A case of extreme hydrocephalus in a 67-year-old man whose professional and social lives were normal.

Neuro-Chirurgie·2021

Search research articles

Related Experiment Video

Updated: May 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Effect of flecainide on left ventricular ejection fraction.

B Brembilla-Perrot¹, M Amor, F Auque

¹Department of Cardiology, CHU Brabois, Vandoeuvre Les Nancy, France.

European Heart Journal

|July 1, 1987

Summary

Oral flecainide did not significantly alter left ventricular (LV) ejection fraction (LVEF) in patients with LV dysfunction. However, caution is advised for patients with severe LV dysfunction due to increased adverse cardiac events.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Related Experiment Videos

Last Updated: May 25, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Area of Science:

Cardiology
Pharmacology

Background:

Antiarrhythmic drugs can impair cardiac contractility and exacerbate heart failure.
The impact of oral flecainide on left ventricular (LV) function in patients with LV dysfunction remains unclear.

Purpose of the Study:

To evaluate the effects of oral flecainide on LV function in patients with pre-existing LV dysfunction.
To assess potential dose-dependent effects of flecainide on LV ejection fraction (LVEF).

Main Methods:

36 patients with LV dysfunction (LVEF ≤ 40%) were enrolled.
LVEF was measured using radionuclide ventriculography before and after 7 days of flecainide therapy.
Patients received either 200 mg/day or 300 mg/day of flecainide.

Main Results:

No significant changes in LVEF were observed in patients who completed the study (n=29) at either dosage.
Seven patients (19%) discontinued therapy due to severe cardiac adverse effects, showing significantly lower LVEF (15 ± 7) compared to completers (27 ± 8).
Patients with severe LV dysfunction (LVEF < 30%) experienced a higher incidence of adverse effects.

Conclusions:

Oral flecainide did not significantly impact LV function in patients with LV dysfunction at standard dosages.
Careful administration of flecainide is recommended for patients with severe LV dysfunction (LVEF < 30%) due to increased risk of cardiac adverse events.